• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

HLA-B Gene Record

  • Summary
  • Interactions
  • Claims
  • HLA-B 3106 Druggable Genome

    Alternate Names:

    3106
    MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B
    HLA-B
    AS
    B-4901
    HLAB
    142830
    4932
    ENSG00000234745
    OTTHUMG00000031153
    PA35056
    HLA class I antigen B-7
    T47415

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (4 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    DRUGGABLE GENOME

    Publications:

    Xu CF et al., 2016, HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer., Clin Cancer Res
    Cai F et al., 2018, Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01., Intern Med J
    Chen WT et al., 2018, The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions., J Invest Dermatol
    Tempark T et al., 2017, Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population., Pharmacogenet Genomics
    Zhang FR et al., 2013, HLA-B*13:01 and the dapsone hypersensitivity syndrome., N Engl J Med
    Wang H et al., 2013, Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China., J Invest Dermatol
    Murata et al., 2004, Reiter's syndrome following intravesical bacille biliE de Calmette-GuErin treatment for superficial bladder carcinoma: report of six cases., Mod Rheumatol
    Hirata K et al., 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study., Pharmacogenomics J
    Valevski A et al., 1998, HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients., Eur J Immunogenet
    Saito T et al., 2016, Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population., Biol Psychiatry
    Lieberman JA et al., 1990, HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia., Arch Gen Psychiatry
    Romero-Gómez M et al., 2003, HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C., Am J Gastroenterol
    Farag RE et al., 2013, Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients., Arch Iran Med
    Alfirevic et al., 2006, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity., Pharmacogenomics
    Yang L et al., 2009, Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome., PLoS Comput Biol
    Cheung CL et al., 2016, HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis., Clin Pharmacol Ther
    Chen PL et al., 2015, Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study., Nat Commun
    Cirulli ET et al., 2019, A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury., Gastroenterology
    Her Y et al., 2011, Stevens-Johnson syndrome induced by acetazolamide., J Dermatol
    Shannon et al., 1994, Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential., Immunopharmacol Immunotoxicol
    Mallal S et al., 2008, HLA-B*5701 screening for hypersensitivity to abacavir., N Engl J Med
    Wuillemin N et al., 2014, T cells infiltrate the liver and kill hepatocytes in HLA-B(∗)57:01-associated floxacillin-induced liver injury., Am J Pathol
    Wuillemin N et al., 2013, HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin., J Immunol
    Phillips EJ et al., 2013, HLA-B*5701 and flucloxacillin associated drug-induced liver disease., AIDS
    Yip VL et al., 2012, HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review., Clin Pharmacol Ther
    Vera JH et al., 2013, The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype., AIDS
    Tassaneeyakul W et al., 2009, Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population., Pharmacogenet Genomics
    Daly AK et al., 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin., Nat Genet
    Locharernkul C et al., 2008, Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population., Epilepsia
    Yang F et al., 2014, HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population., Pharmacogenomics
    Tangamornsuksan W et al., 2019, Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis., Pharmacogenomics J
    Shu C et al., 2015, Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01., Int J Dermatol
    Yang F et al., 2016, HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese., Pharmacogenomics J
    Kim SH et al., 2010, HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis., Pharmacogenomics
    Shirato S et al., 1997, Stevens-Johnson syndrome induced by methazolamide treatment., Arch Ophthalmol
    Yang Y et al., 2017, HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions., Pharmacogenomics J
  • FLOXACILLIN   HLA-B

    Interaction Score: 3.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30664875 18256392 24731753 23596311 23291545 23132554 23032409 19696695 19483685 18637831


    Sources:
    PharmGKB

  • TRICHLOROETHYLENE   HLA-B

    Interaction Score: 2.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FOSPHENYTOIN   HLA-B

    Interaction Score: 2.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • METHAZOLAMIDE   HLA-B

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30242287 25970075 25918017 20504258 9109770


    Sources:
    PharmGKB

  • CLINDAMYCIN   HLA-B

    Interaction Score: 1.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27527109


    Sources:
    PharmGKB

  • DAPSONE   HLA-B

    Interaction Score: 1.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29512326 29458119 28885988 24152261 23604100


    Sources:
    PharmGKB

  • CARBIMAZOLE   HLA-B

    Interaction Score: 1.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26599303 26151496


    Sources:
    PharmGKB

  • CLAVULANIC ACID   HLA-B

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30664875


    Sources:
    PharmGKB

  • ACETAZOLAMIDE   HLA-B

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21342230


    Sources:
    PharmGKB

  • ABACAVIR   HLA-B

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19629158


    Sources:
    FDA

  • METHIMAZOLE   HLA-B

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26599303 26151496


    Sources:
    PharmGKB

  • BCG VACCINE   HLA-B

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17028812


    Sources:
    NCI

  • TICLOPIDINE   HLA-B

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17339877


    Sources:
    PharmGKB

  • MINOCYCLINE   HLA-B

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • AMOXICILLIN   HLA-B

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30664875


    Sources:
    PharmGKB

  • RIBAVIRIN   HLA-B

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12873589 23360626


    Sources:
    PharmGKB

  • SULFASALAZINE   HLA-B

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25303297


    Sources:
    PharmGKB

  • PAZOPANIB   HLA-B

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26546620


    Sources:
    PharmGKB FDA

  • STAVUDINE   HLA-B

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CLOZAPINE   HLA-B

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9587740 26876947 2222133


    Sources:
    PharmGKB

  • CARBAMAZEPINE   HLA-B

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16981842


    Sources:
    NCI FDA

  • THALIDOMIDE   HLA-B

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7876469


    Sources:
    NCI

  • OXCARBAZEPINE   HLA-B

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • LAMIVUDINE   HLA-B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PHENYTOIN   HLA-B

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • Ensembl: ENSG00000234745

    • Version: 101_38

    Alternate Names:
    HLA-B Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: HLA-B

    • Version: 18-August-2020

    Alternate Names:
    PA35056 PharmGKB ID

    Gene Info:

    Publications:
    Cheung CL et al., 2016, HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis., Clin Pharmacol Ther
    Chen PL et al., 2015, Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study., Nat Commun
    Cirulli ET et al., 2019, A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury., Gastroenterology

  • NCI: HLA-B

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Murata et al., 2004, Reiter's syndrome following intravesical bacille biliE de Calmette-GuErin treatment for superficial bladder carcinoma: report of six cases., Mod Rheumatol
    Schmidt et al., 1993, Differential regulation of human leukocyte antigen class I genes by interferon in vivo and in vitro., J Immunother Emphasis Tumor Immunol
    Marincola et al., 1994, Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines., J Immunother Emphasis Tumor Immunol

  • HingoraniCasas: ENSG00000234745

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000234745 Gene Symbol
    HLA-B Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: HLA-B

    • Version: 01-February-2022

    Alternate Names:
    HLAB GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE

    Publications:

  • Tempus: HLA-B

    • Version: 11-November-2018

    Alternate Names:
    HLA-B Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: HLA class I antigen B-7

    • Version: 2020.06.01

    Alternate Names:
    HLA-B TTD Gene Abbreviation
    T47415 TTD Target ID

    Gene Info:

    Publications:

  • FDA: HLA-B

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21